Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2015

01-07-2015 | Pancreatic Tumors

Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer

Authors: Amanda B. Cooper, MD, MS, Rebecca Slack, MS, David Fogelman, MD, Holly M. Holmes, MD, Maria Petzel, RD, Nathan Parker, MS, Aparna Balachandran, MD, Naveen Garg, MD, An Ngo-Huang, Gauri Varadhachary, MD, Douglas B. Evans, MD, Jeffrey E. Lee, MD, Thomas Aloia, MD, Claudius Conrad, MD, Jean-Nicolas Vauthey, MD, Jason B. Fleming, MD, Matthew H. G. Katz, MD

Published in: Annals of Surgical Oncology | Issue 7/2015

Login to get access

Abstract

Background

Little is known about changes in body composition that may occur during neoadjuvant therapy for pancreatic cancer. This study was designed to characterize these changes and their potential relationships with therapeutic outcomes.

Methods

The study population consisted of patients with potentially resectable pancreatic cancer treated on a phase II trial of neoadjuvant chemotherapy and chemoradiation. Skeletal muscle and adipose tissue compartments were measured before and after administration of neoadjuvant therapy using SliceOMatic software (TomoVision, 2012) and protocol-mandated CT scans. Sarcopenia was defined using gender-adjusted norms.

Results

Among 89 eligible patients, 46 (52 %) patients met anthropometric criteria for sarcopenia prior to the initiation of neoadjuvant therapy. Further depletion of skeletal muscle, visceral adipose tissue, and subcutaneous adipose tissue occurred during neoadjuvant therapy, but these losses did not preclude the performance of potentially curative surgery. Degree of skeletal muscle loss correlated with disease-free survival while visceral adipose loss was associated with overall and progression-free survival. However, completion of all therapy, including pancreatectomy, was the only independently significant predictor of outcome in a multivariate analysis of overall survival.

Discussion

These data suggest that body composition analysis of standard CT images may provide clinically relevant information for patients with potentially resectable pancreatic cancer who receive neoadjuvant therapy. Anthropometric changes must be considered in the design of preoperative therapy regimens, and further efforts should focus on maintenance of muscle and visceral adipose tissue in the preoperative setting.
Appendix
Available only for authorised users
Literature
1.
2.
Peng P, Hyder O, Firoozmand A, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:1478–86.PubMedCentralPubMedCrossRef
3.
Dalal S, Hui D, Bidaut L, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Sympt Manag. 2012;44:181–91.CrossRef
4.
Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973–9.PubMedCrossRef
5.
Di Sebastiano KM, Yang L, Zbuk K, et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. Br J Nutr. 2013;109:302–12.PubMedCrossRef
6.
Jacquillat C, Baillet F, Auclerc G, et al. Neoadjuvant chemotherapy of breast cancer. Drugs Exp Clin Res. 1986;12:147–52.PubMed
7.
Scholl SM, Asselain B, Palangie T, et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer. 1991;27:1668–71.PubMedCrossRef
8.
Mehta VK, Poen J, Ford J, et al. Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Dis Colon Rectum. 2001;44:52–8.PubMedCrossRef
9.
Mohiuddin M, Winter K, Mitchell E, et al. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006;24:650–5.PubMedCrossRef
10.
Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165–74.PubMedCrossRef
11.
Walsh TN, Grennell M, Mansoor S, Kelly A. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esophagus. 2002;15:121–4.PubMedCrossRef
12.
Del Fabbro E, Parsons H, Warneke CL, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17:1240–5.PubMedCentralPubMedCrossRef
13.
Awad S, Tan BH, Cui H, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr (Edinburgh). 2012;31:74–7.CrossRef
14.
Clark W, Siegel EM, Chen YA, et al. Quantitative measures of visceral adiposity and body mass index in predicting rectal cancer outcomes after neoadjuvant chemoradiation. J Am Coll Surg. 2013;216:1070–81.PubMedCrossRef
15.
Tempero MA, Malafa MP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2014. J Natl Comp Cancer Netw. 2014;12:1083–93.
16.
Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3487–95.PubMedCrossRef
17.
Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.PubMedCrossRef
18.
Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8:935–49; discussion 949–50.PubMedCrossRef
19.
Evans DB, Lee JE, Tamm EP, Pisters PWT. Pancreaticoduodenectomy (Whipple operation) and total pancreatectomy for cancer. In: Fischer J, editor Master of surgery. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:1299–317.
20.
Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.PubMedCrossRef
21.
Mehta CR, Patel NR. A network algorithm for performing Fisher’s exact test in r x c contingency tables. J Am Stat Assoc. 1983;78:427–34.
22.
Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457–81.CrossRef
23.
Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187–220.
24.
Lausen B, Sauerbrei W, Schumacher V. Classification and regression trees (CART) used for the exploration of prognostic factors measured on different scales. Contr Stat. 1994:483–96.
25.
Shen W, Punyanitya M, Wang Z, et al. Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr. 2004;80:271–8.PubMedCentralPubMed
26.
Shen W, Punyanitya M, Chen J, et al. Visceral adipose tissue: relationships between single slice areas at different locations and obesity-related health risks. Int J Obes (2005). 2007;31:763–9.
27.
Fogelman DR, Holmes H, Mohammed K, et al. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014;5:307–13.
28.
Barret M, Antoun S, Dalban C, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66:583–9.PubMedCrossRef
29.
Wakabayashi H, Sakuma K. Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management. J Cachexia Sarcopenia Muscle. 2014.
30.
Santa Mina D, Clarke H, Ritvo P, et al. Effect of totalbody prehabilitation on postoperative outcomes: a systematic review and meta-analysis. Physiotherapy. 2014;100:196–207.PubMedCrossRef
31.
de Campos-Ferraz PL, Andrade I, das Neves W, Hangai I, Alves CR, Lancha AH Jr. An overview of amines as nutritional supplements to counteract cancer cachexia. J Cachexia Sarcopenia Muscle. 2014;5:105–10.PubMedCentralPubMedCrossRef
32.
Di Girolamo FG, Situlin R, Mazzucco S, Valentini R, Toigo G, Biolo G. Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. Curr Opin Clin Nutr Metab Care. 2014;17:145–50.PubMedCrossRef
33.
34.
Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15:656–66.PubMedCrossRef
35.
Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20:2787–95.PubMedCrossRef
Metadata
Title
Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer
Authors
Amanda B. Cooper, MD, MS
Rebecca Slack, MS
David Fogelman, MD
Holly M. Holmes, MD
Maria Petzel, RD
Nathan Parker, MS
Aparna Balachandran, MD
Naveen Garg, MD
An Ngo-Huang
Gauri Varadhachary, MD
Douglas B. Evans, MD
Jeffrey E. Lee, MD
Thomas Aloia, MD
Claudius Conrad, MD
Jean-Nicolas Vauthey, MD
Jason B. Fleming, MD
Matthew H. G. Katz, MD
Publication date
01-07-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 7/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4285-2

Other articles of this Issue 7/2015

Annals of Surgical Oncology 7/2015 Go to the issue

Colorectal Cancer

Long-Term Survival After High-Dose-Rate Brachytherapy for Locally Advanced or Recurrent Colorectal Adenocarcinoma

Melanomas

Sentinel Lymph Node Biopsy Use Among Melanoma Patients 75 Years of Age and Older

Colorectal Cancer

Effects of Preoperative Chemoradiotherapy on the Likelihood of Sphincter Preservation Surgery in Locally Advanced Distal Rectal Cancer: A Longitudinal Study Based on Pelvic Magnetic Resonance Imaging

Endocrine Tumors

Improving Outcomes in Adrenocortical Cancer: An Australian Perspective

Breast Oncology

Growing Use of Mastectomy for Ductal Carcinoma-In Situ of the Breast Among Young Women in the United States

Gynecologic Oncology

Management of Stage I Endometrial Cancer in France: A Survey on Current Practice